Convalescent plasma as a potential therapy for COVID-19.,The Lancet Infectious Diseases

当前位置： X-MOL 学术 › Lancet Infect Dis › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Convalescent plasma as a potential therapy for COVID-19.
The Lancet Infectious Diseases ( IF 56.3 ) Pub Date : 2020-02-27 , DOI: 10.1016/s1473-3099(20)30141-9
Long Chen ₁ , Jing Xiong ₁ , Lei Bao ₁ , Yuan Shi ₁

Affiliation

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has become a major concern all over the world. The pneumonia induced by the SARS-CoV-2 is named coronavirus disease 2019 (COVID-19). By Feb 22, 2020, this virus has affected more than 77 700 people worldwide and caused more than 2300 deaths. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. Apart from supportive care, such as oxygen supply in mild cases and extracorporeal membrane oxygenation for the critically ill patients, specific drugs for this disease are still being researched. In the USA, the first patient infected with SARS-CoV-2 was treated by supportive care and intravenous remdesivir, before the patient recovered and was discharged. However, randomised clinical trials are needed to evaluate the safety and efficacy of remdesivir in the treatment of COVID-19.

更新日期：2020-03-27

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>